Vienna, 25 September 2008. The acknowledged advance of several vaccine programmes run by AFFiRiS GmbH has prompted broker MIG AG to access its investment in the company. It has set up two new funds - MIG 5 and MIG 7 - to accord clandestine investors in Germany and Austria the befalling to advance in this able biotech company. The aggregation absitively to crop this footfall for two reasons. First, to ensure the aboriginal advantage of approaching basic appeal for the connected acknowledged development of vaccines adjoin Alzheimer's ache and atherosclerosis and, second, the amazing abeyant that the proprietary AFFITOME belvedere technology offers the all-around biologic market.
The investment accumulation MIG-Fonds appear today that it has added its investment in AFFiRiS by a added Euro 3 million. As a result, clandestine investors now accept addition adventitious to allotment in the bread-and-butter success of the biotech aggregation via the MIG Fonds 5 and 7. This account is decidedly accordant for clandestine investors in Germany, who accept actual acceptance to MIG 7. This provides investors with the befalling to accomplish a awful able investment afore the adapted basic assets tax comes into force in Germany. Therefore, afterwards a year's captivation period, any after profits fabricated from this investment will be tax free.
AFFiRiS will accord to the success of these funds through its proprietary AFFITOME technology, which is based on the action of atomic mimicry. This technology enables the development of customized vaccines accepted as AFFITOPE. Dr. Walter Schmidt, co-founder and aggregation CEO, explains the key to the company's AFFiRiS vaccine strategy: "Our patented AFFITOME technology enables scientists to actualize both molecules with actual specific bounden characteristics and molecules that alter in anatomy but display identical bounden characteristics. We are currently application these strengths in the development of vaccines adjoin Alzheimer's disease. In the future, AFFITOME technology will aswell be able to apply a absolute access on added animal rogue proteins - such as lipid metabolism enzymes. In band with our action of developing medicines for diseases with burning medical charge and adorable bazaar potential, one of our next artefact candidates can bear able after-effects in the analysis of atherosclerosis."
Michael Motschmann, Senior Fund Manager at MIG Fonds, comments on business developments at AFFiRiS GmbH: "In an amazingly abbreviate aeon of time, the aggregation has developed two vaccines adjoin Alzheimer's ache from the antecedent abstraction to the aboriginal appearance I analytic trial, appropriately underlining the capability of its awful able business model. We accept every acumen to accept that these vaccines accomplish absorbing artefact candidates and apprehend commensurable developments to chase in added indications. This advance abandoned prompted us to accomplish addition abundant investment. What's more, the AFFITOME technology abaft the development of these vaccines represents an about costive value, which can accomplish the aggregation a actual adorable licenser for above biologic companies."
About AFFiRiS GmbH (as at September 2008):
AFFiRiS GmbH develops peptide-based vaccines for the analysis of Alzheimer's disease, atherosclerosis and added diseases that actively crave a medical solution. The aggregation has accustomed belvedere technologies and registered the agnate apparent families. The aboriginal patents accept already been issued. It employs 35 awful able associates of agents on 600sqm of busy class accessories at the Campus Vienna Biocenter (www.affiris.com).
About MIG-Fonds:
The accord of MIG Verwaltungs AG in Affiris GmbH represents the assiduity of a tried-and-tested approach. Investment is alone fabricated in called companies in Germany and Austria afterwards their activity has been thoroughly audited. Its innovative, high-potential articles and the ambitious abilities of its administration teams are both key. MIG Verwaltungs AG is accurate by Alfred Wieder AG. This specialist in adventure basic is accomplished in the auction of backing and is accordingly the aboriginal point of acquaintance for any abeyant investors.
Contact for AFFiRiS GmbH:
Dr. Walter Schmidt
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 798 15 75-10
E office@affiris.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at
W www.prd.at
2009年12月16日星期三
AFFiRiS AG - AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
Vienna, 23rd June 2009. MIG Fonds and AFFiRiS AG are this year's winners of the 2009 Venture Capital & Private Equity accolade antagonism hosted by the industry annual Boerse-Express and Junge Industrie. The accolade recognised the abiding affiliation amid the German adventure armamentarium and the Austrian biotechnology aggregation as able-bodied as a EUR 430 actor accord amid AFFiRiS and GSK Biologicals.
Last Tuesday MIG Fonds and AFFiRiS AG were awarded aboriginal abode in the Venture Capital and Private Equity (VC / PE) awards of the Austrian industry annual Boerse-Express.com and their co-sponsors Junge Industrie. The winners are called afterward a appropriate alternative action that combines the perspectives of the magazine's readers and called experts, who appraise accumulated success belief from altered perspectives. This year, an investment accord that has been abounding for both adventure ally was recognised and the accent of VC costs for the start-up aeon of avant-garde businesses was thereby recognised.
Dr. Walter Schmidt, co-founder and CEO of AFFiRiS AG, commented that the VC / PE awards "have a actual appropriate acceptation for the basic investment bazaar in Austria because they authenticate the basic action of VC in the development of able high-tech businesses. In our case, three years ago MIG Fonds started to advance a absolute of EUR 11.5 million. Without this capital, our licensing accord with GSK Biologicals three years after would not accept been possible. This accord is for up to EUR 430 actor in upfront and anniversary payments for our Alzheimer’s vaccines. MIG Fonds' accommodation to advance has accordingly already been amiable for anybody involved."
Based on the MIG Fonds investment, AFFiRiS AG was able to advance ist AFFITOME® technology, which delivers avant-garde vaccines with actual specific properties. The close has already appear the development of candidates for ameliorative vaccines adjoin Alzheimer's, Parkinson's and atherosclerosis - in added words, adjoin diseases that accept so far seemed clashing for analysis by vaccination, but that represent markets account billions. Vaccine candidates for four added bearding abiding diseases are currently accepting developed by AFFiRiS AG.
Asked about the success adventure of AFFiRiS AG and the accepted award, Andreas Höfler of Alfred Wieder AG said: "We are actual appreciative of this award. Good investment tends to not alone advance advances in technology, but aswell to advance individuals and aims that are as abstracted as they are clear. Our MIG armamentarium managers aswell pay accurate absorption to ensuring that the ambition markets of our abeyant investees are of a acceptable size, and that the businesses we accounts accept the abeyant to become all-embracing bazaar leaders. We recognised this abeyant in AFFiRiS three years ago - the aboriginal big pharma accord and the accepted accolade affirm our antecedent analysis."
About AFFiRiS AG (as at June 2009)
AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are acclimated to amusement Alzheimer's disease, atherosclerosis, Parkinson's ache and added diseases that actively crave a medical band-aid and which accept ample bazaar potential. Alzheimer's ache is currently the arch adumbration and two abeyant articles are in the final stages of analytic appearance I studies. In October 2008, the aggregation succeeded in accepting GlaxoSmithKline Biologicals as its licensing accomplice for the Alzheimer's vaccine. The arrangement anticipates milestone-dependent
payments of up to EUR 430 million. AFFiRiS currently employs 50 awful able agents and afresh added an added 1,100 sqm to its bounds at the St. Marx campus in Vienna, Austria (www.affiris.com).
Contact for AFFiRiS AG:
Mag. Agnes Meyer
Karl-Farkas-Gasse 22
1030 Vienna
Austria
T +43 / 1 / 798 15 75 - 390
E agnes.meyer@affiris.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at
Last Tuesday MIG Fonds and AFFiRiS AG were awarded aboriginal abode in the Venture Capital and Private Equity (VC / PE) awards of the Austrian industry annual Boerse-Express.com and their co-sponsors Junge Industrie. The winners are called afterward a appropriate alternative action that combines the perspectives of the magazine's readers and called experts, who appraise accumulated success belief from altered perspectives. This year, an investment accord that has been abounding for both adventure ally was recognised and the accent of VC costs for the start-up aeon of avant-garde businesses was thereby recognised.
Dr. Walter Schmidt, co-founder and CEO of AFFiRiS AG, commented that the VC / PE awards "have a actual appropriate acceptation for the basic investment bazaar in Austria because they authenticate the basic action of VC in the development of able high-tech businesses. In our case, three years ago MIG Fonds started to advance a absolute of EUR 11.5 million. Without this capital, our licensing accord with GSK Biologicals three years after would not accept been possible. This accord is for up to EUR 430 actor in upfront and anniversary payments for our Alzheimer’s vaccines. MIG Fonds' accommodation to advance has accordingly already been amiable for anybody involved."
Based on the MIG Fonds investment, AFFiRiS AG was able to advance ist AFFITOME® technology, which delivers avant-garde vaccines with actual specific properties. The close has already appear the development of candidates for ameliorative vaccines adjoin Alzheimer's, Parkinson's and atherosclerosis - in added words, adjoin diseases that accept so far seemed clashing for analysis by vaccination, but that represent markets account billions. Vaccine candidates for four added bearding abiding diseases are currently accepting developed by AFFiRiS AG.
Asked about the success adventure of AFFiRiS AG and the accepted award, Andreas Höfler of Alfred Wieder AG said: "We are actual appreciative of this award. Good investment tends to not alone advance advances in technology, but aswell to advance individuals and aims that are as abstracted as they are clear. Our MIG armamentarium managers aswell pay accurate absorption to ensuring that the ambition markets of our abeyant investees are of a acceptable size, and that the businesses we accounts accept the abeyant to become all-embracing bazaar leaders. We recognised this abeyant in AFFiRiS three years ago - the aboriginal big pharma accord and the accepted accolade affirm our antecedent analysis."
About AFFiRiS AG (as at June 2009)
AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are acclimated to amusement Alzheimer's disease, atherosclerosis, Parkinson's ache and added diseases that actively crave a medical band-aid and which accept ample bazaar potential. Alzheimer's ache is currently the arch adumbration and two abeyant articles are in the final stages of analytic appearance I studies. In October 2008, the aggregation succeeded in accepting GlaxoSmithKline Biologicals as its licensing accomplice for the Alzheimer's vaccine. The arrangement anticipates milestone-dependent
payments of up to EUR 430 million. AFFiRiS currently employs 50 awful able agents and afresh added an added 1,100 sqm to its bounds at the St. Marx campus in Vienna, Austria (www.affiris.com).
Contact for AFFiRiS AG:
Mag. Agnes Meyer
Karl-Farkas-Gasse 22
1030 Vienna
Austria
T +43 / 1 / 798 15 75 - 390
E agnes.meyer@affiris.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at
订阅：
博文 (Atom)